Nuvation Bio Inc. Selling Expense
Nuvation Bio Inc. (NUVB) reported Selling Expense of $911.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingExpense · last filed 2026-08-06
- Nuvation Bio Inc. selling expense for the quarter ending 2026-06-30 was $911.00K, a 429.65% increase year-over-year.
- Nuvation Bio Inc. selling expense for the quarter ending 2026-03-31 was $375.00K.
- Nuvation Bio Inc. selling expense for the quarter ending 2025-06-30 was $172.00K.
- Nuvation Bio Inc. selling expense for the quarter ending 2025-03-31 was $0.00.
- Nuvation Bio Inc. selling expense for fiscal 2025 was $856.00K.
- Nuvation Bio Inc. selling expense for fiscal 2024 was $0.00.
| Period end | Selling Expense 3 month | Selling Expense 6 month | Selling Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $911.00K 10-Q · filed 2026-08-06 | $1.29M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $375.00K 10-Q · filed 2026-05-04 | ||
| 2025-12-31 | $856.00K 10-K · filed 2026-03-02 | ||
| 2025-06-30 | $172.00K 10-Q · filed 2026-08-06 | $172.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |